Corline Biomedical: Ten-year licensing and supply agreement with Kardium - Redeye

Redeye is positive about Corline’s new licensing and supply agreement with Kardium, which underlines the importance of Corline’s CHS surface technology in Kardium’s product offering. Kardium has now received FDA approval, with a US launch expected in the near term. From 2026, Kardium also expects to enter new markets, which are not included in our current valuation. We will therefore release a research update in the near term to incorporate these opportunities.

Länk till analysen i sin helhet: https://www.redeye.se/research/1129107/corline-biomedical-ten-year-licensing-and-supply-agreement-with-kardium?utm_source=finwire&utm_medium=RSS